Archived Newsletters

  1. 08.05.26 -- Global Ties, Good Fortune Bind Biotech And CDMO 8/5/2026
    08/05/26 Outsourced Pharma Newsletter
  2. 08.04.26 -- End-To-End Solutions For Drug Development 8/4/2026
    08/04/26 Outsourced Pharma Newsletter
  3. 08.04.26 -- Platform Strategies For Manufacturable Bispecific Antibodies 8/4/2026

    08/04/26 Outsourced Pharma Newsletter

  4. 08.04.26 -- The Great CDMO Reset: How Sponsor Expectations Are Driving Change 8/4/2026
    08/04/26 Outsourced Pharma Newsletter
  5. 08.03.26 -- STREAM The Strategy: Avoid Scalability Pitfalls, Boost Titers, And Ace Annex 1 8/3/2026
    08/03/26 Outsourced Pharma Newsletter
  6. 08.03.26 -- Global Ties, Good Fortune Bind Biotech And CDMO 8/3/2026
    08/03/26 Outsourced Pharma Newsletter
  7. 07.31.26 -- Repurposing Legacy Infrastructure For Biopharma Resilience 7/31/2026
    07/31/26 Outsourced Pharma Newsletter
  8. 07.30.26 -- Drug Sponsors Are Reshaping Today's CDMOs 7/30/2026
    07/30/26 Outsourced Pharma Newsletter
  9. 07.29.26 -- Key Considerations for Combination Product Development 7/29/2026

    07/29/26 Outsourced Pharma Newsletter

  10. 07.29.26 -- Why Velocity Is External Manufacturing's True Advantage 7/29/2026
    07/29/26 Outsourced Pharma Newsletter